KKPC.F Stock Overview
Produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Kaken Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥22.63 |
52 Week High | JP¥23.96 |
52 Week Low | JP¥22.30 |
Beta | 0.27 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 155.76% |
Recent News & Updates
Recent updates
Shareholder Returns
KKPC.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 0.6% | 1.8% |
1Y | n/a | 22.2% | 24.2% |
Return vs Industry: Insufficient data to determine how KKPC.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KKPC.F performed against the US Market.
Price Volatility
KKPC.F volatility | |
---|---|
KKPC.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: KKPC.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine KKPC.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1917 | 1,135 | Hiroyuki Horiuchi | www.kaken.co.jp |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens.
Kaken Pharmaceutical Co., Ltd. Fundamentals Summary
KKPC.F fundamental statistics | |
---|---|
Market cap | US$925.25m |
Earnings (TTM) | US$49.92m |
Revenue (TTM) | US$448.12m |
18.5x
P/E Ratio2.1x
P/S RatioIs KKPC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KKPC.F income statement (TTM) | |
---|---|
Revenue | JP¥72.04b |
Cost of Revenue | JP¥33.51b |
Gross Profit | JP¥38.54b |
Other Expenses | JP¥30.51b |
Earnings | JP¥8.03b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
Earnings per share (EPS) | 211.91 |
Gross Margin | 53.49% |
Net Profit Margin | 11.14% |
Debt/Equity Ratio | 2.7% |
How did KKPC.F perform over the long term?
See historical performance and comparison